FSIS Directive 10000.1 Policy on Use of Results from Non-FSIS Laboratories


Under certain circumstances, such as during outbreaks or illness investigations, results from non-FSIS laboratories are shared with FSIS. If FSIS decides the results are acceptable, the Agency may take an action (e.g. recommend a recall or detain product). This directive describes the decision-making process FSIS follows to determine appropriate use of the non-FSIStest results. FSIS is reissuing this directive in its entirety to clarify the documentation and information needed by FSIS to complete the review of results provided to FSIS by non-FSIS laboratories.


FSIS Directive 10,000.1, Policy on Use of Results from Non-FSIS Laboratories, 5/11/2007


A. As a public health regulatory agency, FSIS investigates reports of foodborne illness,contamination, and adulteration potentially associated with FSIS-regulated products. Leading up to or during these investigations, non-FSIS laboratories may test FSIS regulated product and share the results with FSIS. FSIS Office ofPublicHealth Science (OPHS)will review the results and associated documentation shared by the non-FSIS laboratory to determine whether FSIS will accept the results.

B. This directive supplements, but does not conflict with or supersede, instructions as specified in FSIS Directive 8080.3, Foodborne Illness Investigations.


A. OPHS assigns a lead investigator to review the results shared by non-FSIS laboratories and consult with other Agency subject matter experts where appropriate.

B. Thelead investigatoristoobtain the external party contactinformation for the non-FSIS laboratory from the appropriate FSIS personnel.

C. The lead investigator is to contact the non-FSIS laboratory to begin the review process. During the initial contact with the non-FSIS laboratory, the lead investigator is to:

        1. Provide a copy of and review the contents of this directive;

        2. Determine what information FSIS needs to complete the review; and

        3. Set a mutually agreeable timeframe for receiving information.

D. Thelead investigatoris toperform the review and coordinate all follow-up meetings with the non-FSIS laboratory, if clarification or more information is needed.

E. To complete the review, the lead investigatoris tofollow and document responses to the criteria in Section V in this directive.

F. Thelead investigatoris todraft asummarydetermination of acceptability and provide that draft with supporting information for OPHS approval.

G. When approved, the lead investigator is to finalize the summary determination ofacceptability and provide it to the appropriate FSISofficials.

H. Thelead investigatoris toensure the information and documentation related to review is appropriately labeled, maintained, and accessible.


A. Thelead investigator istoverify thatthe accredited non-FSIS laboratorycan provide at leastone of the following:

        1. Documentation of accreditation to the ISO 17025 standard through a third-party accreditation body, covering the testing methods performed;

        2. Clinical Laboratory Improvement Amendments (CLIA) certificate covering the testing methods performed; or

        3. The most recentFSISauditdocumentationfor statelaboratoriesthatparticipate in the Meat Poultry Inspection (MPI) program covering the testing methods performed.

B. If the accredited non-FSIS laboratory meets at least one of the criteria in A of this section, thelead investigator istoverify that the laboratory has the following documentation:

        1. A completedform similar tothe FSISForm 8000-17, Evidence Receipt and Chain of Custody (The use of form 8000-17 is not required; it is cited to provide an example of the information needed for documentation);

        2. Laboratory Report, such as:

                a. Laboratory report with sample identification, final results, and authorization by the responsible official for affirming results; and

                b. NationalCenter for BiotechnologyInformation (NCBI)number (if applicable); or

        3. Point of contact information such as e-mail addressand phone number.

C. The lead investigator is to inquire how the laboratory stored the samples, whether sample reserves exist, and whether FSIS can obtain any of the reserves.


A. Thelead investigator is to verify that anon-accredited non-FSIS laboratory can provide,in addition to information in Section VB, the following:

        1. Laboratory Methods:

                a. Copy of the screening, isolation, extraction, clean up, digestion, confirmation, and characterization (e.g., molecular serotyping, whole genome sequencing, etc.) methods used, as applicable;

                b. Method validation/verificationdocumentation showing that thelaboratory method was appropriate for the analyte and matrix;

                c. Test kits documentation and test kit validation information by independentorganizations (e.g., AOAC International, Association Franšaise de Normalisation (AFNOR));

                d. Copy of laboratory procedures and work instructions related to the applicable methods; and

        2. Quality Assurance Records, such as:

                a. Records for lot acceptance to include materials, test kits, buffer, media, mobile phase, columns;

                b. Calibration records for equipment and instrumentation, that correlate with analysis dates;

                c. Sample data and result worksheets/reports documenting the data recorded during the sample analysis; and

                d. Training records forall personnelinvolved in testing procedures,and the last set of laboratory proficiency results.


A. If OPHS determines the non-FSIS laboratory result is acceptable, FSIS may use the result to informAgency action (e.g., recommend a recall or detain product).

B. If OPHS determines the non-FSIS laboratory result is not acceptable:

        1. FSIS may request that remaining sample be submitted to an FSIS laboratory for testing as outlined in FSIS Directive 8080.3, or

        2. FSIS personnel may collect a verification sample if the appropriate product is available, following procedures outlined in FSIS Directive 8010.3, Procedures for Evidence Collection, Safeguarding and Disposal.

C.FSIS will base the collection of reserve or verification samples on the epidemiological linkbetween clinical casesand the product to be tested. FSIS will attempt to collect verificationsamples of the same product and lot code from the same location from which the non-FSISlaboratory collected the previously tested sample.

D.The lead investigator issues an internal report that describes the outcome of the review andassist FSIS program area representatives to ensure factual, technical, and scientific accuracy ofthe non-FSIS laboratory results is maintained during public communications.


Referquestions regarding this directive to the Office of Policy and Program Development through askFSIS, or by telephone at 1-800-233-3935. When submitting a question, use the Submit a Question tab, and enter the following information in the fields provided:
Subject Field: Enter FSIS Directive 10,000.1.
Question Field: Enter question with as much detail as possible.
Product Field: Enter General Inspection from the drop-down menu.
Category Field: Enter Sampling from the drop-down menu. Select
Policy Area: Domestic (U.S.) Only from the drop-down menu.

When all fields are complete, press Continue and at the next screen press Finish Submitting Question.

NOTE: Refer to FSIS Directive 5620.1, Using askFSIS, for additional information on submitting questions.

Rachel A. Edelstein

Assistant Administrator
Office of Policy and Program Development